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Background: Tuberculosis (TB) remains a global public health problem, with developing countries bearing the highest burden. Nigeria 
is first in Africa and sixth in the world among the countries with the highest TB burden, but is among the 10 countries accounting for 
over 70% of the global gap in TB case detection and notification. Enugu State, Nigeria reportedly has a notification gap of almost 14,000 
TB cases; a situation which must be addressed.  
Materials and Methods: A total number of 868 individuals accessing DOTS services in designated centres within the six Local 
Government Areas (LGAs) of Enugu North geographical zone, was recruited into the study. The participants were screened for HIV 
seropositivity by standard protocols, while screening for TB and drug-resistant TB were conducted by a combination of Zhiel Neelsen 
staining and Nucleic Acid Amplification Test (Xpert
® 
MTB/Rif).  
Results: Of the 868 subjects that participated in the study, 176 (20.3%) were HIV seropositive. The highest prevalence (26.7%) of HIV 
was recorded in Udenu LGA, while the least (13.1%) was recorded in Nsukka LGA. Overall TB prevalence was found to be 22.1% and 
21.3% by sputum-smear and NAAT, respectively.  Uzo Uwani LGA recorded the highest prevalence of both TB (33.3%) and TB/HIV 
co-infection (16.7%), but the lowest prevalence of resistant TB. Nsukka LGA had the highest prevalence of resistant TB.  
Conclusion: Enugu North geographical zone, Nigeria, has a high prevalence of both HIV and TB, including resistant TB and there is 
need to increase monitoring of individuals resident in this region.   
   




List of Abbreviations: TB – Tuberculosis, MDRTB – Multidrug-Resistant Tuberculosis, WHO – World Health Organization, HIV – 
Human Immunodeficiency Virus, AIDS – Acquired Immunodeficiency Syndrome, NTBLCP – National Tuberculosis and Leprosy 
Control Programme, LGA – Local Government Area, NPC – National Population Commission, DOTS – Directly Observed Treatment 




Tuberculosis (TB) remains a global public health problem and one of the top ten leading causes of death, worldwide, with 
developing countries bearing the highest burden (WHO, 2020).  In 2018, Nigeria was listed as first in Africa and sixth among the 30 
countries of the world with the highest TB burden (WHO, 2020). Unfortunately, the problem of TB in Nigeria has been complicated by 
the emergence and spread of drug resistant TB and a high burden of HIV/AIDS (NTBLCP, 2017; WHO, 2018). The problem of TB is 
worsened when there is also a high burden of HIV infections, as people with HIV are more likely to develop active TB. According to 
WHO reports, an estimated 63,000 Nigerians living with HIV/AIDS develop TB, while about 39,000 die from the disease, each year 
(WHO, 2018). 
To further compound the problem, Nigeria is ranked among the 10 countries that accounted for 77% of the global gap in TB 
case detection and notification in 2016. It is reported that Nigeria contributes about 8% of the 4.3 million TB cases missed globally.  
Consequently, in 2019, WHO initiated ‘community-informant’ methods to find missing TB cases in Nigerian communities 
(WHO, 2019). The initiative covered 12 high burden states in Nigeria, but Enugu State was not part of the study. However, according to 
NTBLCP (2019), Enugu State has a notification gap of almost 14,000 TB cases.  
This study was conducted in Enugu North geographical zone. The zone comprises six Local Government Areas (LGAs), 
namely, Nsukka, Igbo-Etiti, Uzo-Uwani, Igbo Eze North, Udenu and Igbo Eze South, and had a total ward population of about 1,466,996 
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income generating activities, such as petty trading and peasant farming. In addition, one of the commercial nerve-centres of the zone, 
Obollo Afor, in Udenu LGA, is also a stopover for commercial drivers and people on transit to and from the northern parts of the 
country, making the area a hub for commercial sex activity, with attendant problems, such as HIV transmission. The study was, 
therefore, conducted to determine the prevalence of TB and MDRTB in the six different LGAs of Enugu north geographical zone, with a 
view to fill some of the gap currently existing in TB detection and reporting in Nigeria. 
 
Materials and Methods  
Study area 
 
The study was conducted in Enugu north geographical zone, south eastern Nigeria, which currently constitute Enugu north 
senatorial zone in the state geopolitical arrangement and is comprised of six local government areas (LGAs).  The zone has a total ward 
population of about 1,466,996 (NPC, 2012). The zone is characterized by low socio-economic indicator, with a majority of the residents 
engaging in low-income generating activities, such as small trading and peasant farming. The geographical zone has about 35 DOTS 
centres spread across the six LGAs. Sputum samples were collected from five comprehensive HIV/AIDS treatment sites (2 public health 




























The study group comprised 868 individuals of different age groups (from age 5 and above) accessing DOTS services in the 
designated centres  across the 6 LGAs in the zone; with productive cough or presumptive diagnosis of tuberculosis, who volunteered to 
participate in the study. The survey population for NAAT and drug resistant TB comprised 207 stratified randomly selected individuals 
with productive cough, accessing clinical services in the 35 DOTS centres. The DOTs centres provided the opportunity to collect sputum 
samples from individuals with high suspicion index for tuberculosis, those newly diagnosed and those on treatment but on follow up visit 
to the facilities. Individuals less than 5 years and/or ≥ 5 years who clinically/symptomatically screened positive to tuberculosis but did 




The study was carried out in accordance with the tenets of the declaration of Helsinki. The purpose of this study was explained 
to the subjects in English and Igbo languages. Code numbers rather than names were used to identify them to ensure confidentiality. An 
Informed Consent Form was developed, explained and administered to clients/clients’ care givers (for children from 5 and above).  Only 
consenting clients were enrolled in the study. Participation in the study was completely voluntary and at no cost to the consenting clients.  
Clients were also informed that quality of care in the health facility would not in any way, be affected by their decision to 
participate or not. Approval was obtained from the authorities of district hospitals and the respective DOTS/TB microscopy centres in 
the zone. Ethical clearance was obtained from the Health Research and Ethics Committee of Enugu State Ministry of Health, Enugu 
(Ref. No.: MH/MSD/EC/0183). 
 
Diagnosis of HIV infection 
 
HIV testing was performed on all participants according to the national guidelines for HIV testing, using Determine, Unigold 
and Stat Pak rapid diagnostic test kits, according to the manufacturers’ instructions. The Determine kit was used as the first line strip for 




HIV testing, according to the national guidelines. Positive results were retested with the Unigold kit. However, in the event of a 
discordant result, Stat Pak was used. The final result of the algorithm for a particular sample was scored positive if at least two of the 
three rapid screening HIV assays were reactive. HIV counseling was offered to all subjects with unknown HIV status and those who 
previously tested negative.  
 
Collection and processing of sputum samples 
 
The subjects were advised to rinse their mouth at least twice with water before producing the specimen in order to remove food 
and reduce contaminating bacteria load from their mouths. They were instructed to take two breaths, and then cough deeply and 
expectorate the sputum into provided 50 ml screw-capped translucent bottles, holding the sample container close to their mouth. Three 
sputum specimens (spot, early morning, spot) were collected from each participant under close supervision. The samples were then 
processed for the standard acid-fast direct smear microscopy using Ziehl-Neelsen staining and one of the spot samples processed for 
Rifampicin resistance (MDRTB) assay by Nucleic Acid Amplification Test (NAAT) at Enugu Ezike District Hospital TB laboratory, 
according to the National guidelines. Stained smears were examined for acid-fast bacilli (AFB) under the microscope using oil 
immersion (100X) objectives.  
 
Confirmation of TB and drug-resistant TB  
 
Confirmation of the presence of M. tuberculosis and resistance (MDRTB) were assayed by Nucleic Acid Amplification Test 




Local Government and gender distribution of participants  
 
A total number of 868 individuals was enrolled in the study comprising 420 (48.4%) males and 448 (51.6%) females. Of the 
868 subjects from the six LGAs in the zone, Igbo Eze North had the highest number of participants, with 425 (48.9%) and Igbo Etiti had 
the least number of participants, with 29 (3.3%), as shown in Table 1.  
 
Table 1: Local Government and Gender Distribution of Participants (N = 868) 
 
LGA 





Females (%) Total (%) 
Igbo Etiti 5    18 (2.1)   11(1.3)   29 (3.3) 
Igbo Eze North 5 187(21.5) 238 (27.4) 425 (48.9) 
Igbo Eze South 5   63 (7.3)   65 (7.5) 128 (14.8) 
Nsukka 8   50 (5.8)   34 (3.9)   84 (9.7) 
Udenu 5   81 (9.3)   91(10.5) 172 (19.8) 
Uzo Uwani 7   21(2.4)     9 (1.0)   30 (3.4) 
Total 35 420(48.4) 448 (51.6) 868 
 
HIV seropositivity amongst participants from different LGAs 
 
Out of 868 subjects that participated in the study, 176 (20.3%) were HIV seropositive. Of these, 97 (54.5%) were females and 
79 (45. 5%) males. The difference between male and female seropositivity was however not statistically significant (P < 0.05). Local 
government disaggregation of data on HIV seropositivity in both male and female participants showed that the highest prevalence 
(26.7%) was recorded in Udenu LGA, while the least (13.1%) was recorded in Nsukka LGA. The highest prevalence in males (30.0%) 
was found in Igbo Eze South and the least (9.5%) in Uzo Uwani LGA, while for females, the highest prevalence (33.3%) was found in 
Uzo Uwani and the least (11.6%) in Nsukka LGA (Table 2).  
 
Table 2: HIV seropositivity amongst participants in different LGA 
 













Igbo Etiti              18   4 (22.2)     11   2 (18.2)     6 (20.7)  
Igbo Eze North 187 28 (14.9)  238 48 (20.2)   76 (17.8)  
Igbo Eze South   63 19 (30.0)     65 13 (20.0)   32 (25.0)  
Nsukka   50   7 (14.0)    34   4 (11.6)   11 (13.1)  
Udenu   81 19 (23.5)     91 27 (29.7)   46 (26.7)  
Uzo Uwani   21   2 (9.5)      9   3(33.3)     5 (16.7)  




Prevalence of pulmonary TB in different LGAs in the zone 
 
Of the 868 subjects that participated in the study, 192 (22.1%) tested positive to Ziehl Neelsen staining technique with an 
overall male to female preponderance of approximately 3: 2. The male to female preponderance of sputum smear positivity was 
consistent in all the LGAs sampled except for Uzo Uwani LGA, where there was female to male ratio of 55.6% to 25.9%. Analysis of 
the result showed that there was a significant difference (P < 0.05) between the prevalence of sputum smear positivity in male and 
female subjects that participated in the study. In terms of case detection in LGAs, Uzo Uwani recorded the highest prevalence of sputum 
smear positivity (33.3%), while Igbo Etiti had the least (13.8%) as shown in Table 3.  
 
Table 3: Occurrence of Pulmonary TB in different LGA 












Igbo Etiti                18   3 (16.7)   11   1 (9.0)   4 (13.8) 
Igbo Eze North 187 47 (25.1) 238 41 (17.2)  88 (20.7) 
Igbo Eze South   63 20 (31.7)   65   8 (12.3) 28 (21.9) 
Nsukka   50 14 (28.0)   34   7 (20.6) 21 (25.0) 
Udenu   81 21 (25.9)   91 20 (21.9) 41 (23.8) 
Uzo Uwani   21   5 (23.8)     9   5 (55.6) 10 (33.3) 
Total 420 110(26.2) 448 82 (18.3) 192 (22.1) 
 
TB and HIV co-infection 
 
Among the 868 subjects included in this study, 66 (7.6%) had the double burden of HIV and TB. Local Government 
distribution of the co-infections of HIV/TB showed that Uzo Uwani LGA had the highest prevalence of 16.7%, followed by Igbo Etiti 

























 Report of TB prevalence by gender and age group  
 
The highest prevalence of TB (34%) was found among male subjects in the age group of 35 – 44 years while that of female 
(27%) was in the age group 25 – 34 years. Amongst the young adults and middle aged, ranging from 25 to 64 years, sputum smear 
positivity was recorded more in male subjects within the different age brackets. However, amongst children and adolescents (5 – 24 
years), results showed a female predominance of the sputum smear positivity (Figure 3).  
 
Prevalence 



























Prevalence of MDRTB in different LGAs 
 
Of the 207 sputum samples subjected to NAAT (Xpert
® 
MTB/Rif test), 44 (21.3%) were positive. Of these, 6 (13.6%) were 
resistant. Nsukka LGA had the highest prevalence of resistant TB (30.0%), followed by Udenu LGA (16.7%), while Igbo Etiti and Uzo 
Uwani LGAs had the least prevalence with no resistance (Table 4).   
 





Number Resistant to 
RIF 
 
% RIF Resistance 
Igbo Etiti    3 0 0 
Igbo Eze North  12 1   8.3 
Igbo Eze South  11 1   9.1 
Nsukka  10 3 30.0 
Udenu    6 1 16.7 
Uzo Uwani    2 0 0 




The problem of TB globally has been found to be worsened by HIV/AIDS, as people with HIV have a much higher risk of 
developing active TB. According to health reports, about 45% of HIV-negative people with TB and nearly all HIV-positive people with 
TB, have a high risk of death, without appropriate treatment (WHO, 2020).  HIV and TB, co-infection has been described as a lethal 
combination, as each disease speeds up the other’s progress; a realization which probably led to updating of the WHO TB/HIV treatment 
approach, in 2012, to place persons with HIV on TB-preventive therapy upon confirmation of HIV status, regardless of CD4 count 
(WHO, 2020).  This makes it imperative that such cases be detected promptly and given appropriate treatment.   
In this study, 868 subjects with cough, accessing treatment in DOTS centres within Enugu North geographical zone were 
screened for HIV seropositivity and TB. The prevalence of HIV among the subjects was 20.3%. The highest prevalence (26.7%) was 
recorded in Udenu LGA, while the least (13.1%) was in Nsukka LGA. Within the zone, Nsukka LGA represents the most 
cosmopolitan/urban area, within which a tertiary institution is located. The low prevalence of HIV in Nsukka LGA could be attributed to 
improved lifestyle and better enlightenment of the inhabitants. On the other hand, the high prevalence in Udenu LGA, though 
inconsistent with the reports of Okoli et al., (2013), was not surprising, since the LGA houses one of the commercial nerve-centres of the 
zone, Obollo Afor, which is believed to have a high risk of HIV transmission due to increased number of commercial sex workers. 
The overall prevalence of TB among participants was about 22% and there was a male to female preponderance of 
approximately 3:2,that was consistent in almost all the LGAs. This prevalence was higher than WHO projected national prevalence 
(WHO, 2018). Although the study was a hospital-based analysis (considering that most of the subjects were accessing chest clinics) and 
the findings may not be generalized in terms of prevalence of TB, the trends are nevertheless important. The higher male to female 
infection ratio, is in agreement with WHO reports, which state that globally, men are significantly more at risk of contracting and dying 
from TB than women. In 2017 alone, close to 6 million adult men contracted TB and around 840,000 died from it, compared to an 
































estimated 3.2 million adult women who fell ill and almost half a million who died from the disease (Balasubramanian et al., 2004; WHO 
2018). 
In this study, although Udenu LGA had the highest prevalence of HIV, the highest TB prevalence (33.3%) was recorded in Uzo 
Uwani LGA, despite contributing only 3. 4% of the total participants. In addition, the LGA also recorded the highest HIV/TB co-
infection, suggesting a strong link between the TB infections and HIV, for this LGA. Moreover, this is the only LGA where there was a 
significantly (P<0.05) higher female to male ratio of infection, for both HIV and TB. This trend is potentially attributable to sociocultural 
factors. The LGA has a large population of women and widows, as there is a high death rate among the males. Furthermore, women in 
the area are known to frequently indulge in extra-marital affairs or prostitution for augmentation of income, after which they undergo a 
cleansing ritual, before returning to their husbands. This predisposes the women to high rates of HIV and TB infection. The overall 
prevalence of HIV/TB co-infection in this study was moderately high at 7.6%, while the prevalence in the different LGAs ranges from 
5.6% to 16.7%. The findings are in line with previous studies conducted in Ethiopia (7.5%), Nigeria (7.8%) and Tanzania (8.5%) (Ngowi 
et al., 2008; Iliyasu and Babashani, 2009: Wondimeneh et al., 2012), but lower compared to 32.8% and 36.3% reported in some studies 
from Nigeria (Awoyemi, 2002; Egbe et al., 2016). Analysis of TB prevalence, by gender and age-group also supports a strong link 
between TB and HIV in Enugu North geographical zone, as the TB cases were highest in the age groups, which are more active and have 
higher HIV risks, in both males and females. Age disaggregation showed that 34% of the overall sputum smear positive TB was found 
among male subjects aged 35-44 years while highest prevalence (27%) occurred in females aged 25 – 34 years. 
In this study, the prevalence of drug-resistant TB was 13.6%. This finding is lower than the report of a study in southern 
Nigeria, with prevalence 23.4% (Adejumo et al., 2018) and another from northern Nigeria with prevalence of 14.3% (Fadeyi et al., 
2017). However, the prevalence is relatively high in comparison with reports of studies from other parts of Nigeria and other African 
counties such as Ethiopia and Burundi (Sanders et al., 2006; Osman et al., 2012; Adane et al., 2015; Egbe et al., 2016; Kuyinu et al., 
2018).  The variation in reported prevalence even within the same country may reflect the variations in sample size, access to health care 
facilities, and effectiveness of TB control programmes. A somewhat surprising finding from this study was Udenu LGA having the 
highest prevalence for HIV, while Uzo Uwani had the highest TB prevalence, and the highest prevalence of drug-resistant TB was in 
Nsukka LGA. This can, however, be attributed to the higher number of cases in male subjects, who are of course less likely to visit the 
hospital for care and more likely not to follow through with treatment, as suggested by other reports (Auld et al., 2014: Bor et al., 2015).  
Non-completion of treatment has been the top factor among factors contributing to TB drug-resistance (WHO, 2020). It can be 
concluded from this study that Enugu North geographical zone, Nigeria, has a high prevalence of both HIV and TB, including multidrug 
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